Curewell Capital has made a significant growth equity investment in WeInfuse to support the company’s continued expansion and strategic initiatives. WeInfuse will use the newly secured funds to invest in its foundational software platform for infusion centers and accelerate its home infusion and specialty pharmacy solutions.
To continue delivery of software solutions to providers of specialty infusion services, Curewell and WeInfuse have formed the Infusion Technology Advisory Council (ITAC), assembling industry leaders from the infusion, specialty pharmacy and healthcare technology sectors. As part of the investment, Michael Dal Bello and Ceron Rhee, partners at Curewell Capital, and George Lazenby, Curewell senior advisor and CEO of OrderInsite, will be joining WeInfuse’s board of directors and help lead ITAC. Terms of the transaction were not disclosed.
WeInfuse is a software and technology platform for infusion therapy and medication delivery in the U.S. The software platform powers more than 625 infusion centers across the country.
Curewell Capital is a Los Angeles-based investment firm focused on building industry-leading healthcare companies. Drawing upon decades of investment and operating experience in healthcare services, medical devices, life sciences and pharmaceutical services, Curewell Capital partners with owners and management teams leading companies that improve patient outcomes, reduce cost and foster innovation.
According to data captured in the LevinPro HC database, this transaction marks the 46th eHealth and 13th medical practice management software (MPMS) transaction of 2023.
